NASDAQ · AGIO
Healthcare · Biotechnology
$33.10
Down-$0.03 (-0.09%)
Updated Sep 5, 2026, 6:25 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
AGIO closed at $33.10 after 21 trading sessions, up 2.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $33.13 | $33.50 | $32.92 | $33.10 | 480.16K |
| Sep 3, 2026 | $34.28 | $34.39 | $32.95 | $33.13 | 516.04K |
| Sep 2, 2026 | $34.49 | $34.93 | $33.535 | $34.13 | 771.68K |
| Sep 1, 2026 | $33.60 | $34.34 | $33.21 | $34.21 | 926.96K |
| Aug 31, 2026 | $33.09 | $33.865 | $32.9275 | $33.68 | 1.11M |
| Aug 28, 2026 | $33.94 | $34.36 | $33.27 | $33.32 | 519.74K |
| Aug 27, 2026 | $33.94 | $34.805 | $33.605 | $34.28 | 1M |
| Aug 26, 2026 | $33.84 | $34.43 | $33.24 | $33.99 | 812.04K |
| Aug 25, 2026 | $32.85 | $34.26 | $32.84 | $33.90 | 742.19K |
| Aug 24, 2026 | $33.25 | $33.25 | $32.61 | $32.64 | 635.73K |
| Aug 21, 2026 | $33.62 | $34.085 | $32.95 | $33.09 | 577.55K |
| Aug 20, 2026 | $34.64 | $35.085 | $33.61 | $33.63 | 697.49K |
| Aug 19, 2026 | $35.40 | $35.98 | $34.57 | $35.12 | 1.69M |
| Aug 18, 2026 | $33.53 | $34.83 | $33.46 | $34.40 | 1.19M |
| Aug 17, 2026 | $33.66 | $33.985 | $33.22 | $33.63 | 969.29K |
| Aug 14, 2026 | $33.10 | $33.81 | $32.48 | $33.56 | 1.12M |
| Aug 13, 2026 | $34.35 | $34.65 | $33.31 | $33.47 | 939.12K |
| Aug 12, 2026 | $32.74 | $34.31 | $32.33 | $34.21 | 1.22M |
| Aug 11, 2026 | $33.05 | $33.61 | $32.22 | $32.69 | 938.75K |
| Aug 10, 2026 | $31.87 | $33.10 | $31.71 | $32.59 | 1.07M |
| Aug 7, 2026 | $32.32 | $32.61 | $31.545 | $32.27 | 1.4M |
The latest Smart Investors Daily articles mentioning AGIO.
AGIO research
Company profile and research snapshot.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | JP Morgan | Neutral | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 20, 2026
Agios is leveraging mitapivat across PK deficiency, thalassemia, and sickle cell disease to build a rare disease franchise. Read more on AGIO stock here.
Benzinga · Aug 7, 2026
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
Benzinga · Jul 31, 2026
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
Benzinga · Jul 31, 2026
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGIO.
